Index addition puts Cingulate (NASDAQ: CING) into the Russell 3000E
Rhea-AI Filing Summary
Cingulate Inc. reported two corporate updates. Its subsidiary Cingulate Therapeutics LLC amended the employment agreement with Executive Vice President and Chief Medical Officer Matthew N. Brams, extending his full-time employment trial period from June 30, 2026 to September 30, 2026. The company also announced it has been added to the Russell 3000E® Index, which tracks the performance of approximately 4,000 of the largest investable U.S. equities and is fully reconstituted each June. The press release highlights Cingulate’s focus on its lead ADHD candidate CTx-1301 and its proprietary Precision Timed Release platform, which is designed to deliver medication in multiple timed doses over the day.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
CMO trial period end date: September 30, 2026
Russell 3000E coverage: Approximately 4,000 equities
ADHD prescriptions: 100 million annual prescriptions
+5 more
8 metrics
CMO trial period end date
September 30, 2026
Extended Trial Period for Matthew N. Brams’ full-time employment
Russell 3000E coverage
Approximately 4,000 equities
Number of largest investable U.S. equities in the index
ADHD prescriptions
100 million annual prescriptions
Estimated market size of the U.S. ADHD market
Diagnosed ADHD patients
Over 20 million patients
Total U.S. patients diagnosed with ADHD
Adult ADHD patients
12 million adults
Adults diagnosed with ADHD in the U.S.
Child and teen ADHD patients
Over 8 million under 17
Children and adolescents diagnosed with ADHD in the U.S.
Children on ADHD medication
53.6 percent
Portion of children and teens with ADHD using medication in 2022
Persistent ADHD symptoms
65-90 percent
Children and teens whose ADHD symptoms persist into adulthood
Key Terms
Russell 3000E® Index, Precision Timed Release™ (PTR™), 505(b)(2) pathway, Erosion Barrier Layer (EBL), +2 more
6 terms
Russell 3000E® Index financial
"today announced it has been added to the Russell 3000E® Index."
Precision Timed Release™ (PTR™) medical
"utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology"
505(b)(2) pathway regulatory
"CTx-1301 is being evaluated for the treatment of ADHD under the FDA’s 505(b)(2) pathway."
A 505(b)(2) pathway is a U.S. regulatory route that lets a drug developer get approval by relying in part on existing clinical data or published studies instead of repeating every test. Think of it as building on someone else’s homework to shorten development time and cost. For investors, it signals potentially faster, lower‑risk market entry and a chance for competitive protection compared with starting brand‑new drug approvals.
Erosion Barrier Layer (EBL) technical
"It incorporates a proprietary Erosion Barrier Layer (EBL) providing control of drug release"
Oralogik™ technical
"The EBL formulation, Oralogik™, is licensed from BDD Pharma."
forward-looking statements regulatory
"This press release contains “forward-looking statements” within the meaning of Section 27A"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What did Cingulate Inc. (CING) disclose in this 8-K filing?
Cingulate reported an amendment to its Chief Medical Officer’s employment agreement and announced its addition to the Russell 3000E Index, highlighting both a leadership-related update and a new inclusion in a major U.S. equity benchmark.
How did Cingulate (CING) change Matthew Brams’ employment agreement?
Cingulate’s subsidiary extended the Trial Period for Executive Vice President and Chief Medical Officer Matthew N. Brams’ full-time employment from June 30, 2026 to September 30, 2026, maintaining his trial status for an additional three months before a longer-term decision.
What does inclusion in the Russell 3000E Index mean for Cingulate (CING)?
Cingulate’s addition to the Russell 3000E Index places it among approximately 4,000 of the largest investable U.S. equities. The company states this could enhance visibility with institutional investors and expand market awareness as it advances its development pipeline.
What ADHD market context does Cingulate (CING) describe?
Cingulate notes the U.S. ADHD market has about 100 million annual prescriptions and over 20 million diagnosed patients, including 12 million adults and more than 8 million under 17, underscoring the large patient population its lead candidate CTx-1301 aims to address.
What is Cingulate’s lead ADHD product candidate CTx-1301?
CTx-1301 is a once-daily dexmethylphenidate HCl tablet using Cingulate’s Precision Timed Release platform to deliver three precisely timed medication releases. It is being evaluated for ADHD treatment under the FDA’s 505(b)(2) pathway, targeting rapid onset and full active-day coverage.
How does Cingulate’s Precision Timed Release (PTR) platform work?
Cingulate’s PTR technology uses a proprietary Erosion Barrier Layer around a drug core to control release at predefined times. The barrier erodes at a controlled rate until the drug is released, enabling tablet-in-tablet designs intended to deliver multiple daily doses from a single pill.
AI-generated analysis. How Rhea-AI works. Not financial advice.
